Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgen receptors, and increase growth factors, potentially outperforming minoxidil in recovering hair follicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.

A user suggests that deeper microneedling with Verteporfin injections might help regrow hair in areas with scar tissue, alongside a DHT blocker. Another user explains that hair loss might be due to reduced Wnt/β-Catenin signaling and suggests that treatments like Minoxidil, Finasteride, and microneedling could potentially reverse it.

Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hair follicles to androgens.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.

The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. User questions effectiveness of Redensyl.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. User asks about Redensyl's effectiveness, questioning if it's another ineffective remedy.

User started balding at 16 and began treatment at 18, using RU58841, minoxidil, derma rolling, and peptides. After 6 months, they experienced significant hair regrowth and are happy with the results.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

Melatonin, gingko biloba, and biotin are effective for treating hair loss with good tolerability. Alternatives like dutasteride, minoxidil, and other peptides are also discussed.

The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

A 22-year-old is experiencing hair loss, particularly fuzzy hair in the front, and is concerned about male pattern baldness. Treatments mentioned include Propecia (finasteride), minoxidil, PRP treatments, dermarolling, peppermint oil, and apple cider vinegar.

A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.

Hypoxia may enhance hair growth by stimulating stem cells, but it could also risk fibrosis. Some users humorously discuss extreme methods like choking while using minoxidil, highlighting the need for new treatments.

User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.

A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.

Exploring the idea of using facial hair properties for scalp regeneration in male pattern baldness, considering the potential of transferring androgen-resistant characteristics from facial hair to the scalp. Challenges include complexity, scalability, aesthetics, and safety, but the concept encourages innovative thinking beyond current treatments like Minoxidil, Finasteride, and hair transplants.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

The conversation reflects on how hair loss was portrayed in older movies as a natural part of aging, contrasting with today's media where balding is less visible due to treatments like finasteride and hair transplants. Participants also discuss the difference in societal attitudes towards hair loss and appearance in past generations compared to the present.

Cassiopea claimed that their hair loss treatment, Clascoterone, shows comparable results to finasteride after six months of use. Some users believe Clascoterone could be an additional treatment option for those who do not respond to finasteride.

A 20-year-old male experienced early hair thinning due to male pattern baldness and successfully thickened his hair using oral finasteride and topical minoxidil. The conversation highlights the importance of early action and overcoming fear of medication side effects.

L'Oreal is working on hair cloning, with multiple companies using similar techniques, making hair cloning likely by 2030. The conversation expresses optimism about the progress and potential affordability of hair cloning solutions.

Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

Transgender hormone therapy, including Estradiol Valerate, Spironolactone, and Progesterone Micronized, can reverse male pattern baldness and improve hair health. The user shares their positive experience with hair regrowth after transitioning from male to female.

The user emphasizes hydration, androgen receptors, and a 7-day ejaculation recovery period for appearance enhancement. They suggest Minoxidil, finasteride, and RU58841 for hair loss, along with a diet rich in animal fats, specific exercises, and fasting.

A 21-year-old male diagnosed with telogen effluvium and male pattern baldness started taking finasteride, which initially slowed hair shedding and slightly thickened hair. The doctor recommended iron and vitamin D supplements, and the user is considering minoxidil but wants to stabilize shedding first.

DHT sensitivity at the scalp increases with age, contributing to androgenic alopecia. Treatments like Minoxidil, finasteride, and RU58841 are discussed for managing hair loss.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.